{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menorrhagia/prescribing-information/nonsteroidal-anti-inflammatory-drugs/","result":{"pageContext":{"chapter":{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs","depth":2,"htmlHeader":"","summary":"","htmlStringContent":"<!-- begin item e575ba25-12ec-4e43-8013-a73f0090764c --><!-- end item e575ba25-12ec-4e43-8013-a73f0090764c -->","topic":{"id":"d4abfe41-b89f-5d51-8168-7ff98b4290f9","topicId":"4013d716-0ba5-4984-bfb1-8c7eca832ba8","topicName":"Menorrhagia","slug":"menorrhagia","lastRevised":"Last revised in December 2018","chapters":[{"id":"0e4b035a-9880-5848-b317-d92515f750d7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"98c45e96-1179-53a4-9b74-a5f71fffaebd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes"},{"id":"a232dfd0-a500-5e6b-9ead-3c3c94f0d2cf","slug":"update","fullItemName":"Update"}]},{"id":"cdc50c06-ff06-509a-be3e-1047ea50bc07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e5043cba-12e2-5f47-aac7-4e74d516a7fa","slug":"goals","fullItemName":"Goals"},{"id":"b1ea37fe-6d24-5529-9f7e-c0e49ccba796","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf03761e-6677-5ba5-ac47-f290b7cb66ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"24f740a2-df74-5305-b364-52d1fa68040a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"913b3856-8846-53a2-86c7-f489c766e0f4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c06974-d676-5c1e-bc8f-269a8c65df4f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7d698fba-d82e-55be-bcc0-0ee11398e628","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"aa066829-e43c-5a83-b602-2680d838463a","slug":"definition","fullItemName":"Definition"},{"id":"37436c25-6db1-5e7c-b8fd-7590cd5ca25d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e5c102c5-46d5-5096-bb8b-d2ef0960e353","slug":"causes","fullItemName":"Causes"},{"id":"b7f926cd-7de3-5b25-9697-78920cccf7b7","slug":"complications","fullItemName":"Complications"}]},{"id":"305d1c2b-5b47-5eda-adc5-03782afe2229","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc278e0b-a1a4-54d5-b44c-ddde104596ea","slug":"assessment","fullItemName":"Assessment"},{"id":"1d41d3f0-3049-510f-982a-9d9c39c5d52f","slug":"investigations-for-the-cause-of-menorrhagia","fullItemName":"Investigations for the cause of menorrhagia"}]},{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","fullItemName":"Management","slug":"management","subChapters":[{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid"},{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone"}]},{"id":"5964d183-6ca2-5e15-9a46-bd0c666e6146","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"443b20d0-895a-5b92-810b-17af26ab31e6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"93531fdf-665e-5277-9d61-5b62984a866f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"949f5d38-0e7a-59b8-a641-b1096ac7f3b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd5aaa9a-b897-51a6-b133-d7e4170711df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81610614-c77a-5340-b5b3-721aafb19cc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1c27f-0003-5757-b8a1-90f777106d61","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8fe218e8-4e7d-55af-9b5b-4f2bad344402","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e6c446bd-c33f-5ceb-b8a3-85e78e1feef3","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field a06a601a-60f5-4aa7-a597-a73f009246a7 --><h3>What do I need to know about prescribing a nonsteroidal anti-inflammatory drug?</h3><!-- end field a06a601a-60f5-4aa7-a597-a73f009246a7 -->","summary":"","htmlStringContent":"<!-- begin item 2480b8da-53a5-4c81-a39e-a73f0092474f --><!-- begin field b6b261a5-9f8d-443f-a7cc-a73f009246a7 --><ul><li>The choice of nonsteroidal anti-inflammatory drug (NSAID) includes ibuprofen, naproxen, or mefenamic acid.<ul><li>Only mefenamic acid is specifically licensed for menorrhagia. However, there are concerns that it is more likely to cause seizures in overdose, and it has a low therapeutic window which increases the risk of accidental overdose.</li></ul></li><li>The following doses are recommended:<ul><li>Mefenamic acid — 500 mg three times daily.</li><li>Naproxen — 500 mg as the first dose, then 250 mg every 6–8 hours.</li><li>Ibuprofen — 400 mg three or four times daily.</li></ul></li><li>Advise the woman:<ul><li>To start the NSAID on the first day of bleeding and to continue until bleeding stops, or reduces to satisfactory levels.</li><li>That NSAIDs can be taken for as long as they are beneficial.  </li></ul></li><li>For detailed information on the adverse effects, contraindications, and interactions of NSAIDs, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">RDTC, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>]</p><!-- end field b6b261a5-9f8d-443f-a7cc-a73f009246a7 --><!-- end item 2480b8da-53a5-4c81-a39e-a73f0092474f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}